GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » ROC %

Allena Pharmaceuticals (Allena Pharmaceuticals) ROC % : -377.41% (As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Allena Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Jun. 2022 was -377.41%.

As of today (2024-04-29), Allena Pharmaceuticals's WACC % is 0.00%. Allena Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Allena Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Allena Pharmaceuticals ROC % Historical Data

The historical data trend for Allena Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allena Pharmaceuticals ROC % Chart

Allena Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROC %
Get a 7-Day Free Trial -938.20 -1,468.96 -1,484.11 -848.89 -685.94

Allena Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,444.65 -2,219.82 -572.78 -462.56 -377.41

Allena Pharmaceuticals ROC % Calculation

Allena Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2021 is calculated as:

ROC % (A: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2020 ) + Invested Capital (A: Dec. 2021 ))/ count )
=-47.649 * ( 1 - 0% )/( (1.973 + 11.92)/ 2 )
=-47.649/6.9465
=-685.94 %

where

Allena Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2022 is calculated as:

ROC % (Q: Jun. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2022 ) + Invested Capital (Q: Jun. 2022 ))/ count )
=-27.696 * ( 1 - 0% )/( (8.068 + 6.609)/ 2 )
=-27.696/7.3385
=-377.41 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allena Pharmaceuticals  (OTCPK:ALNAQ) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Allena Pharmaceuticals's WACC % is 0.00%. Allena Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Allena Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Allena Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Newton Executive Park, Suite 202, Newton, MA, USA, 02462
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Executives
Louis Md Brenner officer: See Remarks RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick director 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz officer: Chief Financial Officer 4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan officer: Chief Financial Officer C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p. 10 percent owner C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp 10 percent owner 11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper director, 10 percent owner 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin director, officer: Chief Executive Officer C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139

Allena Pharmaceuticals (Allena Pharmaceuticals) Headlines

From GuruFocus

Allena Pharmaceuticals Provides Clinical and Corporate Update

By GuruFocusNews GuruFocusNews 01-04-2022